Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2023 Nice Insight Reports
Cell & Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking
Monoclonal Antibody & Recombinant Protein: 2023 Market Analysis, CDMO Pricing and Benchmarking
mRNA Vaccines & Therapeutics: 2023 Market Analysis, CDMO Pricing and Benchmarking
Sterile Drug Product: 2023 Market Analysis, CDMO Pricing and Benchmarking
Active Pharmaceutical Ingredients: 2023 Market Analysis, CDMO Pricing and Benchmarking
Antibody Drug Conjugates: 2023 Market Analysis, CDMO Pricing and Benchmarking
Contract Research Organizations: 2023 Market Analysis, Pricing and Benchmarking
Oral Solid Dosage: 2023 Market Analysis, CDMO Pricing and Benchmarking
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
AstraZeneca
56 Articles Available
1
3
Can't find what you're looking for? Try our
advanced search
.
COVID-19 Prevention
AstraZeneca to Supply Canada with 100,000 Doses of Evusheld, a Long-Acting Antibody Combination for the Prevention of COVID-19
PR-M02-22-21
Clinical Data
New Fasenra® Data from the Meltemi Extension Trial Confirm Long-term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years
PR-M06-21-004
Drug Approval
Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes
PR-M05-21-004
COVID-19 Vaccine
HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine
PR-M11-20-031
Vaccine
Cobra Biologics Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate
PR-M11-20-026
COVID-19 Long-Acting AntiBody (LAAB) Combination AZD7442 Rapidly Advances into Phase III Clinical Trials
PR-M10-20-07
Breakthrough Therapy
Farxiga Granted Breakthrough Therapy Designation in U.S. for Chronic Kidney Disease
PR-M10-20-02
AstraZeneca, Oxford SARS-CoV-2 Vaccine Trials Temporarily Paused
PR-M09-20-NI-11
COVID-19 Vaccine
AMRI Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine
PR-M09-20-NI-08
COVID-19 Vaccine
Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222
PR-M08-20-NI-41
Clinical Trials
AstraZeneca Initiates Phase I Clinical Trial Initiated for Monoclonal Antibody Combination for COVID-19
PR-M08-20-NI-38
Flu Vaccine
AstraZeneca Ships FLUMIST QUADRIVALENT Vaccine in the U.S. for 2020-2021 Flu Season
PR-M08-20-NI-25
COVID-19 Vaccine
AstraZeneca Signs COVID-19 Vaccine Deal with Chinese Company
PR-M08-20-NI-12
Collaboration
AstraZeneca and Daiichi Sankyo Enter Collaboration to Develop and Commercialize New Antibody Drug Conjugate
PR-M07-20-NI-41
Approval
AstraZeneca's Breztri Aerosphere Approved in the US for the Maintenance Treatment of COPD
PR-M07-20-NI-37
COVID-19 Vaccine
SGS Signs Analytical Testing Agreement with AstraZeneca for COVID-19 Vaccine Candidate
PR-M07-20-NI-28
Clinical Results
AstraZeneca's Drug Significantly Reduces the Rate of the Composite of Stroke and Death in Patients
PR-M07-20-NI-027
Vaccine Manufacturing
Daiichi Sankyo Announces Start of Discussions with AstraZeneca Regarding Supply in Japan of Novel Coronavirus Vaccine
PR-M06-20-NI-036
Oncology
Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukemia in Two Trials
PR-M06-20-NI-019
Partnership
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring Assays for Minimal Residual Disease
PR-M06-20-NI-011
Collaboration
AstraZeneca to Discover and Develop Novel Therapies Targeting RNA-Modifying Proteins in Oncology Collaboration with Accent Therapeutics
PR-M06-20-NI-005
Oncology
AstraZeneca Collaborates with ArcherDX to Use Personalized Cancer Assays to Detect Minimal Residual Disease in Lung Cancer Trials
PR-M05-20-NI-044
COVID-19 Vaccine
AstraZeneca Advances Response to COVID-19 After Receiving First Commitments for Oxford’s Potential New Vaccine
PR-M05-20-NI-033
Licensing
AstraZeneca Completes Recovery of Global Rights to Brazikumab from Allergan
PR-M05-20-NI-019
1
3
»
